Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine prophylaxis for vestibular paroxysmia
2015-000388-15Phase 3Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carbamazepine in Vestibular Paroxysmia (VP) (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Number of vertigo attacks per month during the 6‑week treatment periods. Started Dec 2015; status: terminated.
02
Drugs
carbamazepine
03
Conditions
Vestibular Paroxysmia (VP)
Beyond the preview
Go deeper on 2015-000388-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000388-15.